Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:
A Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 673-676, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922240
ABSTRACT
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperidines
/
Pleural Neoplasms
/
Carbazoles
/
Tomography, X-Ray Computed
/
Retrospective Studies
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Anaplastic Lymphoma Kinase
/
Lung Neoplasms
/
Mutation
Type of study:
Observational study
/
Screening study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS